文献速递心脑血管急症

高敏心肌肌钙蛋白I浓度低于5 ng/L与疑似急性冠脉综合征患者心脏结局的关联

Association of High-Sensitivity Cardiac Troponin I Concentration With Cardiac Outcomes in Patients With Suspected Acute Coronary Syndrome.
PubMed 文献 · JAMA · 2017-01-01
一句话结论疑似急性冠脉综合征患者就诊时高敏肌钙蛋白I低于5 ng/L,30天心肌梗死或心源性死亡阴性预测值99.5%,可识别低危人群。

该系统评价与个体患者数据荟萃分析检索2006年1月1日至2017年3月18日MEDLINE、EMBASE、Cochrane和Web of Science数据库,纳入19个队列、9个国家、22457例疑似急性冠脉综合征患者(平均年龄62岁,SD 15.5;女性9329例,41.5%)。就诊时高敏肌钙蛋白I低于5 ng/L者11012例(49%),其中30天主要终点(心肌梗死或心源性死亡)漏诊事件60例(59例指数心肌梗死、1例30天心肌梗死、0例30天心源性死亡),阴性预测值99.5%(95%CI 99.3%-99.6%)。30天无心脏死亡,1年心脏死亡7例(0.1%),阴性预测值99.9%(95%CI 99.7%-99.9%)。作者结论认为该阈值可识别30天心肌梗死或心源性死亡低危患者,但需进一步研究其临床效用和成本效益。

要点

  • 就诊时高敏肌钙蛋白I低于5 ng/L者占49%(11012/22457),30天心肌梗死或心源性死亡阴性预测值99.5%(95%CI 99.3%-99.6%)。
  • 该低危组30天漏诊事件60例:59例指数心肌梗死、1例30天心肌梗死、0例30天心源性死亡。
  • 该低危组1年心源性死亡7例(0.1%),心源性死亡阴性预测值99.9%(95%CI 99.7%-99.9%)。
  • 作者结论:低于5 ng/L可识别30天心肌梗死或心源性死亡低危患者,但需进一步研究该风险分层方法的临床效用和成本效益。

适用人群与场景

  • 疑似急性冠脉综合征患者,来自9个国家19个前瞻性队列,纳入标准为测量高敏心肌肌钙蛋白I浓度并按心肌梗死通用定义判定诊断。
  • 荟萃分析共22457例,平均年龄62岁(SD 15.5),女性9329例(41.5%)。

诊断标准与关键阈值

  • 就诊时高敏心肌肌钙蛋白I浓度低于5 ng/L作为低危识别阈值。
  • 诊断判定依据心肌梗死通用定义。

研究设计与关键结果

  • 系统评价与个体患者数据荟萃分析:检索2006年1月1日至2017年3月18日MEDLINE、EMBASE、Cochrane和Web of Science,19个队列(17个队列获个体患者数据、2个队列聚合数据),采用二项-正态随机效应模型。
  • 22457例中30天主要终点(心肌梗死或心源性死亡)发生2786例(12.4%)。
  • 高敏肌钙蛋白I低于5 ng/L者11012例(49%),30天主要终点阴性预测值99.5%(95%CI 99.3%-99.6%)。
  • 该组30天漏诊事件60例(59例指数心肌梗死、1例30天心肌梗死、0例30天心源性死亡);30天无心脏死亡,1年心脏死亡7例(0.1%),心源性死亡阴性预测值99.9%(95%CI 99.7%-99.9%)。

证据类型、等级与局限

  • 证据类型:系统评价与个体患者数据荟萃分析,纳入19个前瞻性队列。
  • 局限:作者结论指出需进一步研究该风险分层方法的临床效用和成本效益。

对床旁实践的改变

  • 作者认为,就诊时高敏心肌肌钙蛋白I低于5 ng/L可识别30天心肌梗死或心源性死亡低危患者。
  • 作者指出,需进一步研究该风险分层方法的临床效用和成本效益。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: High-sensitivity cardiac troponin I testing is widely used to evaluate patients with suspected acute coronary syndrome. A cardiac troponin concentration of less than 5 ng/L identifies patients at presentation as low risk, but the optimal threshold is uncertain.

OBJECTIVE: To evaluate the performance of a cardiac troponin I threshold of 5 ng/L at presentation as a risk stratification tool in patients with suspected acute coronary syndrome.

DATA SOURCES: Systematic search of MEDLINE, EMBASE, Cochrane, and Web of Science databases from January 1, 2006, to March 18, 2017.

STUDY SELECTION: Prospective studies measuring high-sensitivity cardiac troponin I concentrations in patients with suspected acute coronary syndrome in which the diagnosis was adjudicated according to the universal definition of myocardial infarction.

DATA EXTRACTION AND SYNTHESIS: The systematic review identified 19 cohorts. Individual patient-level data were obtained from the corresponding authors of 17 cohorts, with aggregate data from 2 cohorts. Meta-estimates for primary and secondary outcomes were derived using a binomial-normal random-effects model.

MAIN OUTCOMES AND MEASURES: The primary outcome was myocardial infarction or cardiac death at 30 days. Performance was evaluated in subgroups and across a range of troponin concentrations (2-16 ng/L) using individual patient data.

RESULTS: Of 11 845 articles identified, 104 underwent full-text review, and 19 cohorts from 9 countries were included. Among 22 457 patients included in the meta-analysis (mean age, 62 [SD, 15.5] years; n = 9329 women [41.5%]), the primary outcome occurred in 2786 (12.4%). Cardiac troponin I concentrations were less than 5 ng/L at presentation in 11 012 patients (49%), in whom there were 60 missed index or 30-day events (59 index myocardial infarctions, 1 myocardial infarction at 30 days, and no cardiac deaths at 30 days). This resulted in a negative predictive value of 99.5% (95% CI, 99.3%-99.6%) for the primary outcome. There were no cardiac deaths at 30 days and 7 (0.1%) at 1 year, with a negative predictive value of 99.9% (95% CI, 99.7%-99.9%) for cardiac death.

CONCLUSIONS AND RELEVANCE: Among patients with suspected acute coronary syndrome, a high-sensitivity cardiac troponin I concentration of less than 5 ng/L identified those at low risk of myocardial infarction or cardiac death within 30 days. Further research is needed to understand the clinical utility and cost-effectiveness of this approach to risk stratification.

来源:JAMA,查看原文。版权归原作者所有。

参考来源

  1. Chapman AR, Lee KK, McAllister DA, et al. Association of High-Sensitivity Cardiac Troponin I Concentration With Cardiac Outcomes in Patients With Suspected Acute Coronary Syndrome. JAMA. 2017. PMID: 29127948. doi:10.1001/jama.2017.17488

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。